Exelixis, INC Form 4 insider transactions

Julie Smith, a director at Exelixis, Inc., sold 27,280 shares of common stock on May 21, 2024, at an average price of $21.12.

Director George Poste exercised options to acquire 11,686 shares of Exelixis common stock at $19.57 and sold the same amount at an average price of $20.96.

Director Stelios Papadopoulos exercised stock options and sold shares of Exelixis, Inc. on May 20, 2024.

Exelixis CEO Michael Morrissey reports the withholding of shares to cover taxes related to vesting restricted stock units.

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, reported the withholding of shares to cover taxes related to vesting restricted stock units.

Patrick J. Haley, EVP, Commercial at Exelixis, Inc., reports changes in beneficial ownership of company stock due to tax withholdings upon vesting of restricted stock units.

EVP, General Counsel & Secretary of Exelixis, Jeffrey Hessekiel, reports disposition of shares to cover tax obligations upon vesting of restricted stock units and holdings in the company's 401(k) plan.

Christopher J. Senner, EVP and CFO of Exelixis, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Director Jack L. Wyszomierski exercised stock options and sold shares of Exelixis, Inc. on May 13, 2024, according to a Form 4 filing with the SEC.

Director Alan M. Garber of Exelixis, Inc. reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.

Amy C. Peterson, EVP of Product Development & Medical Affairs and CMO at Exelixis, Inc., reports the acquisition of 82,121 shares of common stock through restricted stock units.

A Form 4 filing reveals that Aftab Dana, CSO/EVP of Discovery & Translational Research at Exelixis, received a stock award and reports holdings in the company's 401(k) plan.

Exelixis CEO Michael Morrissey reports the acquisition of 241,670 shares of common stock through restricted stock units, increasing his total holdings.

Christopher J. Senner, EVP and CFO of Exelixis, Inc., reports acquiring 82,121 shares of common stock through restricted stock units and holding 751,990 shares directly and 2,723 indirectly through a 401(k).

Jeffrey Hessekiel, EVP, General Counsel & Secretary of Exelixis, reports acquisition of 63,350 shares of common stock and disposal of 999 shares through 401(k).

Patrick J. Haley, EVP, Commercial at Exelixis, reports acquisition of 63,350 shares through restricted stock units and disposition of 47,020 shares of common stock at $21.45.